New treatments for idiopathic thrombocytopenic purpura: Rethinking old hypotheses

Expert Opinion on Investigational Drugs

Volumn 18, Issue 6, 2009, Pages 805-819

  Arnold, Donald M ^a   Nazi, Ishac ^a   Kelton, John G ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Autoantibodies; Idiopathic thrombocytopenia purpura; Megakaryocytes; Platelets; Thrombopoietin

Indexed keywords

AKR 501; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; DEXAMETHASONE; ELTROMBOPAG; ERYTHROPOIETIN; GMA 161; HEMOPOIETIC GROWTH FACTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; LGD 4665; MDX 33; MONOCLONAL ANTIBODY; NPLATE; PLACEBO; PREDNISONE; RECOMBINANT THROMBOPOIETIN; RETICULIN; RHESUS ANTIBODY; RITUXIMAB; ROMIPLOSTIM; SB 559448; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR; TOTROMBOPAG; UNCLASSIFIED DRUG;

ARTERY THROMBOSIS; BACTERIAL INFECTION; BONE MARROW DISEASE; CARDIOPULMONARY INSUFFICIENCY; CATARACT; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; DRUG WITHDRAWAL; GUILLAIN BARRE SYNDROME; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEPATOBILIARY DISEASE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN DEFICIENCY; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; KIDNEY COLIC; LEUKOPENIA; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG EMBOLISM; MALIGNANT NEOPLASTIC DISEASE; MEGAKARYOCYTE; MEGAKARYOPOIESIS; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN SECRETION; REVIEW; SEPSIS; SERUM SICKNESS; SIDE EFFECT; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOEMBOLISM; THROMBOSIS; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; BENZOIC ACIDS; BLOOD PLATELETS; CARRIER PROTEINS; DRUGS, INVESTIGATIONAL; HUMANS; HYDRAZINES; IMMUNOLOGIC FACTORS; MODELS, BIOLOGICAL; MODELS, IMMUNOLOGICAL; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PYRAZOLES; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN;

EID: 67649643535     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780902905848     Document Type: Review

References (125)

1. Kaushansky K. Thrombopoietin and the hematopoietic stem cell. Blood 1998;92(1):1-3 (Pubitemid 28303167)
2. Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994;369(6481):565-568
3. Stefanich E, Senn T, Widmer R, et al. Metabolism of thrombopoietin (TPO) in vivo: determination of the binding dynamics for TPO in mice. Blood 1997;89(11):4063-4070
4. Wendling F. Thrombopoietin: its role from early hematopoiesis to platelet production. Haematologica 1999;84(2):158-166 (Pubitemid 29479663)
5. Harker LA. Physiology and clinical applications of platelet growth factors. Curr Opin Hematol 1999;6(3):127-134 (Pubitemid 29467535)
6. Kaushansky K. Thrombopoietin. N Engl J Med 1998;339(11):746-754
7. de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994;369(6481):533-538
8. Italiano JE Jr, Lecine P, Shivdasani RA, Hartwig JH. Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes. J Cell Biol 1999;147(6):1299-1312 (Pubitemid 30012814)
9. Patel SR, Richardson JL, Schulze H, et al. Differential roles of microtubule assembly and sliding in proplatelet formation by megakaryocytes. Blood 2005;106(13):4076-4085
10. Tablin F, Castro M, Leven RM. Blood platelet formation in vitro: the role of the cytoskeleton in megakaryocyte fragmentation. J Cell Sci 1990;97(1):59-70 (Pubitemid 120023246)
11. Hartley PS. Platelet senescence and death. Clin Lab 2007;53(3-4):157-166 (Pubitemid 46656571)
12. Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 1994;91(23):11104-11108 (Pubitemid 24349634)
13. Sohma Y, Akahori H, Seki N, et al. Molecular cloning and chromosomal localization of the human thrombopoietin gene. FEBS Lett 1994;353(1):57-61
14. Wendling F, Maraskovsky E, Debili N, et al. cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature 1994;369(6481):571-574 (Pubitemid 2089104)
15. Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med 2006;354(19):2034-2045
16. Kobayashi M, Laver JH, Kato T, et al. Thrombopoietin supports proliferation of human primitive hematopoietic cells in synergy with steel factor and/or interleukin-3. Blood 1996;88(2):429-436
17. Ku H, Yonemura Y, Kaushansky K, Ogawa M. Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice. Blood 1996;87(11):4544-4551 (Pubitemid 26000290)
18. Ramsfjell V, Borge OJ, Veiby OP, et al. Thrombopoietin, but not erythropoietin, directly stimulates multilineage growth of primitive murine bone marrow progenitor cells in synergy with early acting cytokines: distinct interactions with the ligands for c-kit and FLT3. Blood 1996;88(12):4481-4492
19. Ramsfjell V, Borge OJ, Cui L, Jacobsen SE. Thrombopoietin directly and potently stimulates multilineage growth and progenitor cell expansion from primitive (CD34+ CD38-) human bone marrow progenitor cells: distinct and key interactions with the ligands for c-kit and flt3, and inhibitory effects of TGF-beta and TNF-alpha. J Immunol 1997;158(11):5169-5177 (Pubitemid 127681219)
20. Sitnicka E, Lin N, Priestley GV, et al. The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells. Blood 1996;87(12):4998-5005
21. Zeigler FC, de SF, Widmer HR, et al. In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. Blood 1994;84(12):4045-4052
22. Foster DC, Sprecher CA, Grant FJ, et al. Human thrombopoietin: gene structure, cDNA sequence, expression, and chromosomal localization. Proc Natl Acad Sci USA 1994;91(26):13023-13027
23. Sungaran R, Markovic B, Chong BH. Localization and regulation of thrombopoietin mRNa expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood 1997;89(1):101-107 (Pubitemid 26428183)
24. Kuter DJ. Thrombopoietin: biology and clinical applications. Oncologist 1996;1(1 & 2):98-106 (Pubitemid 126669377)
25. Broudy VC, Lin NL, Sabath DF, et al. Human platelets display high-affinity receptors for thrombopoietin. Blood 1997;89(6):1896-1904
26. Fielder PJ, Gurney AL, Stefanich E, et al. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1996;87(6):2154-2161
27. Li J, Xia Y, Kuter DJ. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br J Haematol 1999;106(2):345-356 (Pubitemid 29450656)
28. Fielder PJ, Hass P, Nagel M, et al. Human platelets as a model for the binding and degradation of thrombopoietin. Blood 1997;89(8):2782-2788
29. Kaushansky K. Thrombopoietin: basic biology and clinical promise. Leukemia 1997;11(Suppl 3):426-427 (Pubitemid 27313557)
30. Scheding S, Bergmann M, Shimosaka A, et al. Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo. Transfusion 2002;42(3):321-327
31. Kuter DJ, Rosenberg RD. Appearance of a megakaryocyte growth-promoting activity, megapoietin, during acute thrombocytopenia in the rabbit. Blood 1994;84(5):1464-1472 (Pubitemid 24273014)
32. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002;100(10):3457-3469 (Pubitemid 35303910)
33. Alexander WS, Roberts AW, Nicola NA, et al. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood 1996;87(6):2162-2170
34. de Sauvage FJ, Carver-Moore K, Luoh SM, et al. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med 1996;183(2):651-656 (Pubitemid 26059523)
35. Vigon I, Mornon JP, Cocault L, et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci USA 1992;89(12):5640-5644
36. Marsh JC, Gibson FM, Prue RL, et al. Serum thrombopoietin levels in patients with aplastic anaemia. Br J Haematol 1996;95(4):605-610 (Pubitemid 26423360)
37. Methia N, Louache F, Vainchenker W, Wendling F. Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood 1993;82(5):1395-1401 (Pubitemid 23263953)
38. Wolber EM, Jelkmann W. Thrombopoietin: the novel hepatic hormone. News Physiol Sci 2002;17:6-10
39. Ihara K, Ishii E, Eguchi M, et al. Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci USA 1999;96(6):3132-3136
40. Sabath DF, Kaushansky K, Broudy VC. Deletion of the extracellular membrane-distal cytokine receptor homology module of Mpl results in constitutive cell growth and loss of thrombopoietin binding. Blood 1999;94(1):365-367 (Pubitemid 29300171)
41. Feese MD, Tamada T, Kato Y, et al. Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment. Proc Natl Acad Sci USA 2004;101(7):1816-1821
42. Kuroki R, Hirose M, Kato Y, et al. Crystallization of the functional domain of human thrombopoietin using an antigen-binding fragment derived from neutralizing monoclonal antibody. Acta Crystallogr D Biol Crystallogr 2002;58(Pt 5):856-858
43. Gurney AL, Wong SC, Henzel WJ, de Sauvage FJ. Distinct regions of c-Mpl cytoplasmic domain are coupled to the JAK-STAT signal transduction pathway and Shc phosphorylation. Proc Natl Acad Sci USA 1995;92(12):5292-5296
44. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura (ITP) of adults and children: Report from an International Working Group. Blood 2008;113(11):2386-2393
45. Feudjo-Tepie MA, Robinson NJ, Bennett D. Prevalence of diagnosed chronic immune thrombocytopenic purpura in the US: analysis of a large US claim database: a rebuttal. J Thromb Haemost 2008;6(4):711-712
46. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97(9):2549-2554
47. Berchtold P, McMillan R. Therapy of chronic idiopathic thrombocytopenic purpura in adults. Blood 1989;74(7):2309-2317 (Pubitemid 19286446)
48. Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000;160(11):1630-1638 (Pubitemid 30367902)
49. McMillan R, Bussel JB, George JN, et al. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol 2008;83(2):150-154
50. Warner MN, Moore JC, Warkentin TE, et al. A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenic purpura. Br J Haematol 1999;104(3):442-447 (Pubitemid 29119263)
51. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346(13):995-1008
52. Goodnow CC. Multistep pathogenesis of autoimmune disease. Cell 2007;130(1):25-35 (Pubitemid 47031326)
53. Olsson B, Andersson PO, Jacobsson S, et al. Disturbed apoptosis of T-cells in patients with active idiopathic thrombocytopenic purpura. Thromb Haemost 2005;93(1):139-144
54. Liu B, Zhao H, Poon MC, et al. Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol 2007;78(2):139-143 (Pubitemid 46058876)
55. Olsson B, Andersson PO, Jernas M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003;9(9):1123-1124
56. Bettaieb A, Fromont P, Louache F, et al. Presence of cross-reactive antibody between human immunodeficiency virus (HIV) and platelet glycoproteins in HIV-related immune thrombocytopenic purpura. Blood 1992;80(1):162-169
57. Takahashi T, Yujiri T, Shinohara K, et al. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. Br J Haematol 2004;124(1):91-96 (Pubitemid 38021628)
58. Asahi A, Nishimoto T, Okazaki Y, et al. Helicobacter pylori eradication shifts monocyte Fc-gamma receptor balance toward inhibitory Fc-gamma-RIIB in immune thrombocytopenic purpura patients. J Clin Invest 2008;118(8):2939-2949
59. Stoll D, Cines DB, Aster RH, Murphy S. Platelet kinetics in patients with idiopathic thrombocytopenic purpura and moderate thrombocytopenia. Blood 1985;65(3):584-588 (Pubitemid 15131466)
60. Heyns AP, Badenhorst PN, Lotter MG, et al. Platelet turnover and kinetics in immune thrombocytopenic purpura: results with autologous 111In-labeled platelets and homologous 51Cr-labeled platelets differ. Blood 1986;67(1):86-92
61. Ballem PJ, Segal GM, Stratton JR, et al. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987;80(1):33-40 (Pubitemid 17097513)
62. Kosugi S, Kurata Y, Tomiyama Y, et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol 1996;93(3):704-706 (Pubitemid 26167375)
63. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373(9664):641-648
64. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371(9610):395-403
65. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007;146(1):25-33
66. Stasi R, Del Poeta G, Stipa E, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007;110(8):2924-2930
67. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88(1):3-40
68. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003;120(4):574-596
69. Mazzucconi MG, Fazi P, Bernasconi S, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 2007;109(4):1401-1407
70. Pamuk GE, Pamuk ON, Baslar Z, et al. Overview of 321 patients with idiopathic thrombocytopenic purpura. Retrospective analysis of the clinical features and response to therapy. Ann Hematol 2002;81(8):436-440
71. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004;104(9):2623-2634 (Pubitemid 39434940)
72. Marcaccio MJ. Laparoscopic splenectomy in chronic idiopathic thrombocytopenic purpura. Semin Hematol 2000;37(3):267-274 (Pubitemid 30612905)
73. Sampath S, Meneghetti AT, MacFarlane JK, et al. An 18-year review of open and laparoscopic splenectomy for idiopathic thrombocytopenic purpura. Am J Surg 2007;193(5):580-583 (Pubitemid 46559904)
74. Bisharat N, Omari H, Lavi I, Raz R. Risk of infection and death among post-splenectomy patients. J Infect 2001;43(3):182-186 (Pubitemid 34211099)
75. Centers for disease control and prevention. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence. MMWR 1993;42(RR-4)
76. Arnold DM, Kelton JG. Current options for the treatment of idiopathic thrombocytopenic purpura. Semin Hematol 2007;44(4 Suppl 5):S12-23 (Pubitemid 350256799)
77. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16(8):2825-2833 (Pubitemid 28363048)
78. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350(25):2572-2581 (Pubitemid 38758544)
79. George JN, Woodson RD, Kiss JE, et al. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher 2006;21(1):49-56
80. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 2005;106(7):2244-2251 (Pubitemid 41510792)
81. Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003;171(3):1581-1587 (Pubitemid 36900094)
82. Golay J, Gramigna R, Facchinetti V, et al. Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab. Br J Haematol 2002;119(4):923-929 (Pubitemid 35463815)
83. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin*s lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001;61(13):5137-5144 (Pubitemid 32681546)
84. Zaja F, Battista ML, Pirrotta MT, et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica 2008;93(6):930-933
85. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004;125(2):232-239 (Pubitemid 38534976)
86. Zaja F, Vianelli N, Sperotto A, et al. B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica 2003;88(5):538-546
87. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006;54(2):613-620 (Pubitemid 43228639)
88. Roll P, Palanichamy A, Kneitz C, et al. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006;54(8):2377-2386
89. Uchida J, Lee Y, Hasegawa M, et al. Mouse CD20 expression and function. Int Immunol 2004;16(1):119-129
90. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108(10):3295-3301
91. Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 2008;112(4):999-1004
92. Zaja F, Baccarani M, Mazza P, et al. A Prospective Randomized Study Comparing Rituximab and Dexamethasone Vs Dexamethasone Alone in ITP: results of final analysis and long term follow up. ASH Annual Meeting Abstracts. 2008;112(11):1
93. Rafailidis PI, Kakisi OK, Vardakas K, Falagas ME. Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. Cancer 2007;109(11):2182-2189 (Pubitemid 46805005)
94. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54(9):2793-2806
95. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005;106(5):1538-1543
96. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy following rituximab therapy in HIV negative patients: a report of 57 cases from the Research on Adverse Drug Event and Reports (RADAR) project. Blood Online 2009
97. Sabath BF, Major EO. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J Infect Dis 2002;186(Suppl 2):S180-6 (Pubitemid 35370479)
98. Du Pasquier RA, Kuroda MJ, Zheng Y, et al. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 2004;127(Pt 9):1970-1978
99. Calabrese LH, Molloy ES, Huang D, Ransohoff RM. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum 2007;56(7):2116-2128 (Pubitemid 47173558)
100. FDA. Rituximab information, 2006. Available from: http://www.fda.gov/ cder/drug/infopage/rituximab/default.htm. [Accessed 24 January 2009]
101. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001;98(12):3241-3248
102. Hokom MM, Lacey D, Kinstler OB, et al. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 1995;86(12):4486-4492
103. Schiffer CA, Miller K, Larson RA, et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 2000;95(8):2530-2535
104. Vadhan-Raj S, Verschraegen CF, Bueso-ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 2000;132(5):364-368
105. Zhao YQ, Wang QY, Zhai M, et al. A multi-center clinical trial of recombinant human thrombopoietin in chronic refractory idiopathic thrombocytopenic purpura. Zhonghua Nei Ke Za Zhi 2004;43(8):608-610
106. Nomura S, Dan K, Hotta T, et al. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 2002;100(2):728-730
107. Harker LA, Carter RA, Marzec UM. Correction of thrombocytopenia and ineffective platelet production in patients infected with human immunodeficiency virus (HIV) by PEG-rHuMGDF therapy. Blood 1998;92(Suppl 1):707a
108. Kuter DJ. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med 2009;60:193-206
109. Basser RL, O'Flaherty E, Green M, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002;99(7):2599-2602
110. Broudy VC, Lin NL. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine 2004;25(2):52-60 (Pubitemid 38018897)
111. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004;76(6):628-638 (Pubitemid 39601552)
112. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis- stimulating protein, for chronic ITP. N Engl J Med 2006;355(16):1672-1681 (Pubitemid 44583957)
113. Newland A, Caulier MT, Kappers-Klunne M, et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 2006;135(4):547-553 (Pubitemid 44583422)
114. Bussel JB, Kuter DJ, Pullarkat V, et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009;113(10):2161-2171
115. Erickson-Miller CL, DeLorme E, Tian SS, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 2005;33(1):85-93
116. Safonov IG, Heerding DA, Keenan RM, et al. New benzimidazoles as thrombopoietin receptor agonists. Bioorg Med Chem Lett 2006;16(5):1212-1216
117. Kuter DJ. New thrombopoietic growth factors. Blood 2007;109(11):4607-4616 (Pubitemid 46827750)
118. Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007;109(11):4739-4741
119. Cheng G, Saleh MN, Bussel JB, et al. Oral eltrombopag for the long-term treatment of patients with chronic idiopathic thrombocytopenic purpura: Results of a Phase III, Double- Blind, Placebo-Controlled Study (RAISE). ASH Annual Meeting Abstracts. 2008;112(11):400
120. Bussel JB, Cheng G, Saleh MN, et al. Safety and efficacy of long-term treatment with oral eltrombopag for chronic idiopathic thrombocytopenic purpura. ASH Annual Meeting Abstracts. 2008;112(11):3432
121. Desjardins RE, Tempel DL, Lucek R, Kuter DJ. Single and multiple oral doses of AKR-501 (YM477) increase the platelet count in healthy volunteers. ASH Annual Meeting Abstracts. 2006;108(11):477
122. Andemariam B, Psaila B, Bussel JB. Novel thrombopoietic agents. Hematology Am Soc Hematol Educ Program 2007;2007:106-113
123. Li X, Hou M. Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs 2008;13(2):237-254 (Pubitemid 351957347)
124. Podolanczuk A, Lazarus AH, Crow AR, et al. Of mice and men: an open label pilot study for treatment of immune thrombocytopenic purpura (ITP) by an inhibitor of Syk. Blood 2009;113(14):3154-3160
125. Oatis W, Shankaran V, Saghir F, et al. A predictive cost-effectiveness analysis of the treatment of chronic, refractory immune thrombocytopenic purpura (ITP) with novel agents: an economic model based on long-term treatment data with Rituximab versus Romiplostim. ASH Annual Meeting Abstracts. 2008;112(11):3433